Literature DB >> 19539765

Can recreational doses of THC produce significant dopamine release in the human striatum?

Paul R A Stokes1, Mitul A Mehta, H Valerie Curran, Gerome Breen, Paul M Grasby.   

Abstract

BACKGROUND: Cannabis use in early adolescence may be a risk factor for development of schizophrenia. In animals, Delta9-tetrahydrocannabinol (THC) increases the rate of dopamine neuronal firing and release in the striatum. Thus cannabis use may increase dopamine release in the human striatum leading to vulnerability to psychosis. AIMS: To investigate whether THC, the main psychoactive component of cannabis, can produce dopamine release in the human striatum.
METHODS: Thirteen healthy volunteers, with previous cannabis experience, underwent two [11C]-raclopride positron emission tomography (PET) scans to indirectly measure striatal dopamine levels following either 10 mg THC or placebo.
RESULTS: Although THC markedly increased psychosis-like symptoms on the Psychotomimetic States Inventory (PSI), there was no significant effect of THC on [11C]-raclopride binding.
CONCLUSION: In the largest study of its kind so far, we have shown that recreational cannabis users do not release significant amounts of dopamine from an oral THC dose equivalent to a standard cannabis cigarette. This result challenges current models of striatal dopamine release as the mechanism mediating cannabis as risk factor for schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19539765     DOI: 10.1016/j.neuroimage.2009.06.029

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  40 in total

1.  Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity.

Authors:  Nora D Volkow; Gene-Jack Wang; Frank Telang; Joanna S Fowler; David Alexoff; Jean Logan; Millard Jayne; Christopher Wong; Dardo Tomasi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

Review 2.  The why behind the high: determinants of neurocognition during acute cannabis exposure.

Authors:  Johannes G Ramaekers; Natasha L Mason; Lilian Kloft; Eef L Theunissen
Journal:  Nat Rev Neurosci       Date:  2021-05-27       Impact factor: 34.870

Review 3.  The effects of Δ9-tetrahydrocannabinol on the dopamine system.

Authors:  Michael A P Bloomfield; Abhishekh H Ashok; Nora D Volkow; Oliver D Howes
Journal:  Nature       Date:  2016-11-17       Impact factor: 49.962

4.  Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies.

Authors:  Suhas Ganesh; Jose Cortes-Briones; Mohini Ranganathan; Rajiv Radhakrishnan; Patrick D Skosnik; Deepak Cyril D'Souza
Journal:  Int J Neuropsychopharmacol       Date:  2020-12-03       Impact factor: 5.176

5.  Dopamine release in chronic cannabis users: a [11c]raclopride positron emission tomography study.

Authors:  Nina B L Urban; Mark Slifstein; Judy L Thompson; Xiaoyan Xu; Ragy R Girgis; Sonia Raheja; Margaret Haney; Anissa Abi-Dargham
Journal:  Biol Psychiatry       Date:  2012-01-29       Impact factor: 13.382

6.  Predictors of marijuana relapse in the human laboratory: robust impact of tobacco cigarette smoking status.

Authors:  Margaret Haney; Gillinder Bedi; Ziva D Cooper; Andrew Glass; Suzanne K Vosburg; Sandra D Comer; Richard W Foltin
Journal:  Biol Psychiatry       Date:  2012-08-29       Impact factor: 13.382

7.  Impact of Cannabis Use on the Development of Psychotic Disorders.

Authors:  Samuel T Wilkinson; Rajiv Radhakrishnan; Deepak Cyril D'Souza
Journal:  Curr Addict Rep       Date:  2014-06-01

8.  Acute effect of the anti-addiction drug bupropion on extracellular dopamine concentrations in the human striatum: an [11C]raclopride PET study.

Authors:  Alice Egerton; John P Shotbolt; Paul R A Stokes; Ella Hirani; Rabia Ahmad; Julia M Lappin; Suzanne J Reeves; Mitul A Mehta; Oliver D Howes; Paul M Grasby
Journal:  Neuroimage       Date:  2009-12-05       Impact factor: 6.556

9.  Striatal D(2)/D(3) receptor availability is inversely correlated with cannabis consumption in chronic marijuana users.

Authors:  Daniel S Albrecht; Patrick D Skosnik; Jennifer M Vollmer; Margaret S Brumbaugh; Kevin M Perry; Bruce H Mock; Qi-Huang Zheng; Lauren A Federici; Elizabeth A Patton; Christine M Herring; Karmen K Yoder
Journal:  Drug Alcohol Depend       Date:  2012-08-19       Impact factor: 4.492

10.  The 3rd Schizophrenia International Research Society Conference, 14-18 April 2012, Florence, Italy: summaries of oral sessions.

Authors:  Brandon Abbs; Rashmin M Achalia; Adegoke O Adelufosi; Ahmet Yiğit Aktener; Natalie J Beveridge; Savita G Bhakta; Rachael K Blackman; Emre Bora; M S Byun; Maurice Cabanis; Ricardo Carrion; Christina A Castellani; Tze Jen Chow; M Dmitrzak-Weglarz; Charlotte Gayer-Anderson; Felipe V Gomes; Kristen Haut; Hiroaki Hori; Joshua T Kantrowitz; Taishiro Kishimoto; Frankie H F Lee; Ashleigh Lin; Lena Palaniyappan; Meina Quan; Maria D Rubio; Sonia Ruiz de Azúa; Saddichha Sahoo; Gregory P Strauss; Aleksandra Szczepankiewicz; Andrew D Thompson; Antonella Trotta; Laura M Tully; Hiroyuki Uchida; Eva Velthorst; Jared W Young; Anne O'Shea; Lynn E Delisi
Journal:  Schizophr Res       Date:  2012-08-19       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.